Paxalisib joins a second platform study - Pacific Paediatric Nero-Oncology Consortium (PNOC) for DIPG.
Kazia ongoing study cost (to supply Paxalisib for the study).
Bell Potter overview and 12 months valuation of AU$2.76.
Impressive clinical trial program for Paxalisib,
Kazia and Big Phara ongoing partnership negotiations continuing.
https://kza.irmau.com/irm/PDF/39527662-3bf3-40cb-9034-0c8ef55bfce1/BellPotterKaziaTherapeuticsPaxalisibJoinsASecondPlatformStudy
Regards.
Paxalisib joins a second platform study - Pacific Paediatric...
Add to My Watchlist
What is My Watchlist?